ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.

Gregory W Roloff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.